Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 11/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.77 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.77 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.77 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.77 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.77 |
| ▸ | CSNK1A1L | Q8N752 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.67 |
| ▸ | GCGR | P47871 | 7/20 | 0.67 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | FRK | P42685 | 2/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.63 |
| ▸ | GSK3B | P49841 | 2/20 | 0.63 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.63 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7243804 | 0.88 | ALOX5 (0.79) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL458366 | 0.87 | MAPK14 (1.00) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL9201148 | 0.87 | MAPK14 (1.00) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL4336547 | 0.87 | MAPK14 (1.00) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| Hydrochloric Acid SCHEMBL16566835 | 0.86 | MAPK14 (0.98) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL7067529 | 0.84 | ALOX5 (0.75) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL5698659 | 0.81 | ALOX5 (0.75) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL2649482 | 0.80 | MAPK14 (1.00) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL2648558 | 0.80 | MAPK14 (0.74) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 | |
| SCHEMBL1387814 | 0.80 | ALOX5 (1.00) | ALOX5MAPK14MAPK11CSNK1DCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889887-A4 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORP (US) | 2003-06-11 | — | — | EP | claimed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | claimed |
| US-6235760-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS | SMITHKLINE BEECHAM CORPORATION | 2001-05-22 | — | — | US | claimed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | claimed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | claimed |
| EP-0889887-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-13 | — | — | EP | claimed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | claimed |
| WO-1997035855-A1 | NOVEL TREATMENT FOR CNS INJURIES | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-02 | — | — | WO | claimed |
| US-6645989-B2 | Antiinflammatory agents | SMITHKLINE BEECHAM CORPORATION | 2003-11-11 | — | — | US | disclosed |
| US-20030064997-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2003-04-03 | — | — | US | disclosed |
| US-6268370-B1 | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2001-07-31 | — | — | US | disclosed |
| EP-0906099-A4 | A METHOD OF TREATING CANCER | MERCK & CO INC (US) | 2001-02-07 | — | — | EP | disclosed |
| EP-0934270-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5916891-A | CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0906099-A1 | A METHOD OF TREATING CANCER | Merck & Co., Inc. (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997045412-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997036587-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5656644-A | CYTOKINE SUPPRESSORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064997-A1 | Novel compounds | BRD4, BRDT, HDAC6 | ALOX5 2555/4885MAPK14 3769/4885MAPK11 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.